Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STERIS plc Director's Dealing 2021

Jun 4, 2021

30229_dirs_2021-06-04_01e75b5a-9a19-49a6-861c-32d9c501f14d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STERIS plc (STE)
CIK: 0001757898
Period of Report: 2021-06-02

Reporting Person: Breeden Richard C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-02 Ordinary Shares A 160 Acquired 34962 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 27242 Indirect

Footnotes

F1: Received in exchange for 475 shares of Cantel Medical Corp. ("Cantel") common stock in connection with the acquisition of Cantel by STERIS plc ("STERIS") pursuant to a series of transactions ("Mergers"). Holders of Cantel common stock received $16.93 in cash and 0.33787 STERIS ordinary shares per Cantel share outstanding immediately prior to the Mergers.

F2: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC is in turn the general partner of Breeden Partners L.P. (the "Fund").

F3: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares.